Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance

Authors

Maciej J. Zamek-Gliszczynski, GlaxoSmithKline, USA
Mitchell E. Taub, Boehringer Ingelheim Pharmaceuticals, Inc.
Paresh P. Chothe, Vertex Pharmaceuticals, Inc.
Xiaoyan Chu, Merck & Co., Inc.
Kathleen M. Giacomini, University of California, San Francisco
Richard B. Kim, Western UniversityFollow
Adrian S. Ray, Gilead Sciences Incorporated
Sophie L. Stocker, UNSW Medicine
Jashvant D. Bingham, Google LLC
Zhuozhi Wang, Hospital for Sick Children University of Toronto
Giovanna Pellecchia, Hospital for Sick Children University of Toronto
Janet A. Buchanan, Hospital for Sick Children University of Toronto
Susan Walker, Hospital for Sick Children University of Toronto
Christian R. Marshall, Hospital for Sick Children University of Toronto
Mohammed Uddin, Hospital for Sick Children University of Toronto
Mehdi Zarrei, Hospital for Sick Children University of Toronto
Eric Deneault, Hospital for Sick Children University of Toronto
Lia D'Abate, Hospital for Sick Children University of Toronto
Ada J.S. Chan, Hospital for Sick Children University of Toronto
Stephanie Koyanagi, Hospital for Sick Children University of Toronto
Tara Paton, Hospital for Sick Children University of Toronto
Sergio L. Pereira, Hospital for Sick Children University of Toronto
Ny Hoang, Hospital for Sick Children University of Toronto
Worrawat Engchuan, Hospital for Sick Children University of Toronto
Edward J. Higginbotham, Hospital for Sick Children University of Toronto
Karen Ho, Hospital for Sick Children University of Toronto

Document Type

Article

Publication Date

11-1-2018

Journal

Clinical Pharmacology and Therapeutics

Volume

104

Issue

5

First Page

890

Last Page

899

URL with Digital Object Identifier

10.1002/cpt.1112

Abstract

This white paper provides updated International Transporter Consortium (ITC) recommendations on transporters that are important in drug development following the 3rd ITC workshop. New additions include prospective evaluation of organic cation transporter 1 (OCT1) and retrospective evaluation of organic anion transporting polypeptide (OATP)2B1 because of their important roles in drug absorption, disposition, and effects. For the first time, the ITC underscores the importance of transporters involved in drug-induced vitamin deficiency (THTR2) and those involved in the disposition of biomarkers of organ function (OAT2 and bile acid transporters).